Publications by authors named "Willy Roth"

Claim this Profile
P
Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin.
Joachim Stangier, Hildegard Stähle, Karin Rathgen, Willy Roth, Kathrin Reseski

J Clin Pharmacol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers.
Akihiro Yamada, Kazuya Maeda, Naoki Ishiguro, Yasuhiro Tsuda, Takashi Igarashi, Willy Roth

Pharmacogenet Genomics· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
Joachim Stangier, Karin Rathgen, Hildegard Stähle, Kathrin Reseski, Thomas Körnicke, Willy Roth

Am J Cardiovasc Drugs· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans.
Holger Fuchs, Jean-Paul Tillement, Saik Urien, Andreas Greischel, Willy Roth

J Pharm Pharmacol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment.
Joachim Stangier, Hildegard Stähle, Karin Rathgen, Willy Roth, Kasra Shakeri-Nejad

J Clin Pharmacol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide.
Naoki Ishiguro, Kazuya Maeda, Asami Saito, Wataru Kishimoto, Soichiro Matsushima, Willy Roth

Drug Metab Dispos· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.
Stefan Blech, Thomas Ebner, Eva Ludwig-Schwellinger, Joachim Stangier, Willy Roth

Drug Metab Dispos· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Joachim Stangier, Karin Rathgen, Hildegard Stähle, Dietmar Gansser, Willy Roth

Br J Clin Pharmacol· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modelling the anti-migraine effects of BIBN 4096 BS: a new calcitonin gene-related peptide receptor antagonist.
Iñaki F Trocóniz, Jan-Markus Wolters, Christiane Tillmann, Hans G Schaefer, Willy Roth

Clin Pharmacokinet· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans.
Naoki Ishiguro, Kazuya Maeda, Wataru Kishimoto, Asami Saito, Akiko Harada, Willy Roth

Drug Metab Dispos· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic modelling of BIBN 4096 BS, the first compound of the new class of calcitonin gene-related peptide receptor antagonists.
Iñaki F Trocóniz, Jan-Markus Wolters, Hans Guenter Schaefer, Willy Roth

Eur J Pharm Sci· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Altered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice.
Andreas Leusch, Astrid Volz, Gabriele Müller, Andrea Wagner, Achim Sauer, Willy Roth

Eur J Pharm Sci· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis